Ann: June Quarterly Activity and Cashflow Report, page-34

If you read more closely, the cash they used last quarter was $2,006,000. They have $1,877,000 left which is less than what they spent last quarter. They have also committed $615,000 this quarter to their ArtemiC Phase II clinical trials. This leaves $1,262,000 in their kitty.

This beats my expectation of them running out of money by October.

Looking at the current market depth of buyers and sellers, there is 49 buyers for 8,568,325 shares and 141 sellers for 23,673,269. There will be a lot more sellers come Monday and many will miss out.